(TheNewswire)
|
|||||||||
|
|||||||||
Edmonton, May 8, 2025 – TheNewswire - Innovotech Inc. (TSX-V: IOT) reports that its subsidiary Innovotech Labs Corporation is receiving advisory services and research and development funding of up to $150,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of new antimicrobial testing services for use with medical devices such as catheters, implants, and wound dressings.
The new testing methods align with upcoming changes in international regulatory standards and medical device manufacturers’ needs in the areas of proliferation, biofilm formation, and translocation of microorganisms.
Innovotech Labs Corporation is also receiving funding of up to $30,000 CAD through the NRC IRAP Youth Employment Program to support the hiring of a young graduate to work on the development of antimicrobial silver compounds with properties complementary to InnovoSIL™-1 silver for expanded applications.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Chief Scientific Officer Patricia Nadworny.
About Innovotech
Innovotech Inc. is a diversified Canadian technology company with business operations in a growing portfolio of specialized laboratory services, biotechnology businesses, and proprietary intellectual property. Innovotech Inc. manages several subsidiary companies. Innovotech Labs Corporation is a contract research organization that owns and provides proprietary devices for antimicrobial testing in multiple applications and commercializes antimicrobial silver solutions. Learn more at www.innovotech.ca . Keystone Labs Inc. is a DEL-accredited lab serving the Canadian pharmaceutical industry and industrial markets. Learn more at www.keystonelabs.ca. Innovotech Inc. owns a 60% stake in NouLife Sciences Inc., a company holding intellectual property related to antioxidant molecules with potential applications in cosmetics and various medical conditions including neuropathies.
Patricia Nadworny, Ph.D, B.Sc, P.Eng
Chief Scientific Officer
Innovotech Labs Corporation
780-448-0585 ext. 7
patricia.nadworny@innovotech.ca
Craig Milne, CEO Innovotech Inc.
+1-604-239-1819 craig.milne@innovotech.ca
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
###
Copyright (c) 2025 TheNewswire - All rights reserved.
